This phase 3, nonrandomized, externally controlled trial found that the addition of DCVax-L to SOC was associated with a clinically meaningful and statistically significant extension of overall survival in both nGBM and rGBM. — Dr. Linda Liau, et al, Journal of American Medical Association. November 17, 2022
It is the cornerstone of all combo trials. It has in some cases been a cure all on its own but it is definitely proven to be very powerful in combination with other treatments. She has not walked away from DC-VAX. if given the resources she would run 100 more trials and in EVERY SINGLE ONE OF THEM SHE WOULD USE DCVAX AS THE BACKBONE